John P. Butler - Jun 13, 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Jun 13, 2023
Transactions value $
-$40
Form type
4
Date filed
6/15/2023, 04:28 PM
Previous filing
Mar 3, 2023
Next filing
Oct 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award $0 +47.8K +144.68% $0.00 80.9K Jun 13, 2023 Direct F1
transaction ZYNE Common Stock Sale -$40 -115 -0.14% $0.35 80.8K Jun 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYNE Stock Option (right to buy) Award $0 +71.7K $0.00 71.7K Jun 13, 2023 Common Stock 71.7K $0.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3 The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.